Stadler R, Otte H G
Department of Dermatology, Minden Medical Center, University of Münster, Germany.
Recent Results Cancer Res. 1995;139:391-401. doi: 10.1007/978-3-642-78771-3_30.
The efficacy of a combination treatment with interferon alpha-2a and photochemotherapy was investigated in 16 patients with cutaneous T cell lymphoma. During the initial treatment, interferon alpha-2a was given subcutaneously at maximum dose of 9 million IU. Simultaneously, photo-chemotherapy with a maximum single dose of 3.0 J/cm2 was applied. After a complete or partial remission had been achieved, the dose of interferon was continued as permanent treatment at 3-9 million IU a week. Photochemotherapy was maintained twice a week for a minimum of 2 months and then stopped depending on the course of the disease. The combination treatment was well tolerated and all patients responded to the initial therapy. Three patients were withdrawn at an early stage of therapy, as they developed erythrodermia after photochemotherapy. The permanent treatment led to a complete remission in ten out of 13 patients and to a partial remission in three patients. During the follow-up period (now 10-40 months), therapy was stopped in four patients because of progression and in one patient because of newly diagnosed Hodgkin's disease. In another three patients, who developed local recurrences, a repetition of the initial treatment schedule was necessary to keep them in remission.
对16例皮肤T细胞淋巴瘤患者研究了干扰素α-2a与光化学疗法联合治疗的疗效。在初始治疗期间，皮下注射干扰素α-2a，最大剂量为900万国际单位。同时，应用最大单剂量为3.0 J/cm2的光化学疗法。在达到完全或部分缓解后，继续使用干扰素剂量进行维持治疗，每周300 - 900万国际单位。光化学疗法每周维持两次，至少持续2个月，然后根据病情停止治疗。联合治疗耐受性良好，所有患者对初始治疗均有反应。3例患者在治疗早期退出，因为他们在光化学疗法后出现了红皮病。维持治疗使13例患者中的10例完全缓解，3例部分缓解。在随访期（目前为10 - 40个月），4例患者因病情进展停止治疗，1例患者因新诊断为霍奇金病停止治疗。另外3例出现局部复发的患者，需要重复初始治疗方案以维持缓解状态。
